Penwest Initiates Dosing in Phase I Parkinson’s Trial

July 11, 2008

Penwest Pharmaceuticals has initiated dosing in a Phase I clinical trial of PW 4153, a drug candidate for the treatment of the symptoms of Parkinson’s disease.

The purpose of the Phase I trial of PW 4153 is to assess the bioavailability and pharmacokinetic blood levels of Penwest’s formulation of the drug in healthy volunteers.

PW 4153 is an extended release reformulation of a marketed drug that is dosed multiple times a day. The goal of this formulation is to extend the dosing interval of the drug while minimizing the peak-to-trough ratio, which Penwest believes may enhance the efficacy, tolerability and convenience of the drug for Parkinson’s patients.

Jennifer Good, president and CEO of Penwest, said: “We are pleased to have initiated this Phase I trial of PW 4153, a product candidate that leverages Penwest’s strengths in both reformulation and drug development. We expect to have data from this trial to share in the fourth quarter of 2008.”

comments powered by Disqus